Anatara Lifesciences reports on GaRP-IBS trial expansion

Anatara Lifesciences (ASX:ANR), a developer of evidence-based solutions for gastrointestinal diseases, has provided an update on the expansion of recruitment for Stage 2 of its pivotal GaRP-IBS trial. The company has enrolled 36 participants and activated 2 additional trial sites in Adelaide and the Sunshine Coast of Queensland, demonstrating strong recruitment progress.

Executive Commentary on GaRP-IBS trial expansion

Anatara's Executive Chair Dr. David Brookes expressed, 'The additional trials sites provide the opportunity for IBS sufferers in further geographical locations to participate and will bolster enrolment to ensure adequate numbers through Stage 2 in the required time frame. We were encouraged by the eagerness of these new sites to be involved in the trial of our GaRP product as potentially an emerging treatment for a difficult medical condition and also by their empathy for the participants.'

Summary of GaRP-IBS trial expansion and outlook

Anatara Lifesciences is making significant progress in the recruitment for Stage 2 of its pivotal GaRP-IBS trial, with 36 participants enrolled and 2 new trial sites activated in Adelaide and the Sunshine Coast of Queensland. The company aims to complete recruitment for Stage 2 in Q4 CY2024, with headline results readout anticipated in late Q1 CY2025. The expansion to new geographical locations and the strong interest at both existing and new sites indicate a positive momentum for the trial. The GaRP-IBS trial is designed to confirm the interim results from Stage 1 and address the unmet need for an effective IBS treatment. Anatara's GaRP product has the potential to positively impact a substantial proportion of the population suffering from digestive disorders, presenting a significant market opportunity. The company's commitment to delivering real outcomes for patients and its focus on building a pipeline of human health products position it for potential success in addressing the complexity of gastrointestinal tract conditions.